LFCR Q3 2022 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$256M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$37M-16.3% YoY

Gross Profit

$13M34.4% margin

Operating Income

-$9M-22.9% margin

Net Income

-$13M-35.0% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-13.9%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$23M

Stock-Based Comp.

$622,000

Balance Sheet

Total Assets

$326M

Total Liabilities

$182M

Stockholders' Equity

$144M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$45M	-16.3%
Gross Profit	$13M	$14M	-10.9%
Operating Income	-$9M	$2M	-451.0%
Net Income	-$13M	-$5M	-138.0%